直接口服抗凝剂在老年非瓣膜性房颤抗凝治疗有效性与安全性方面的最新进展

Recent Advances in the Effectiveness and Safety of Direct Oral Anticoagulation in Elderly Non-Valvular Atrial Fibrillation

年龄是心房颤动的独立危险因素,且老年非瓣膜性房颤患者卒中发病率高。评估老年非瓣膜性房颤患者抗凝治疗的有效性及安全性、制定个体化抗凝治疗方案,均是临床工作的重点。近年来的研究表明,直接口服抗凝剂在有效性及安全性方面均优于华法林。不同的直接口服抗凝剂对比,阿哌沙班在有效性及安全性方面优于达比加群酯和利伐沙班。

A high incidence of stroke in elderly patients with non-valvular AF, age is an independent risk factor for atrial fibrillation. Evaluating the effectiveness and safety of anticoagulant therapy and making individualized anticoagulation treatment plan are the focus of clinical work. Recent studies have shown that direct oral anticoagulants were superior to warfarin in terms of effectiveness and safety. By comparing different direct oral anticoagulants, apixaban outperformed dabigatran and rivaroxaban.